Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT

Katrin Resch; Ryan Hung; Jonathan Abele

doi:10.1186/s41824-022-00134-5

European Journal of Hybrid Imaging (Jul 2022)

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT

Katrin Resch,
Ryan Hung,
Jonathan Abele

Affiliations

Katrin Resch: Department of Radiology and Diagnostic Imaging, 2A2.41 WC Mackenzie Health Sciences Centre, University of Alberta
Ryan Hung: Department of Radiology and Diagnostic Imaging, 2A2.41 WC Mackenzie Health Sciences Centre, University of Alberta
Jonathan Abele: Department of Radiology and Diagnostic Imaging, 2A2.41 WC Mackenzie Health Sciences Centre, University of Alberta

DOI: https://doi.org/10.1186/s41824-022-00134-5
Journal volume & issue: Vol. 6, no. 1
pp. 1 – 5

Abstract

Read online

Abstract A 62-year-old man with resected, pathology-proven small bowel neuroendocrine tumor underwent 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT to assess metastatic disease. The 111In-pentetreotide SPECT/CT scan showed no metastatic disease. Both 18F-DOPA and 68Ga-HA-DOTATATE PET/CT showed hepatic and peritoneal metastatic disease. However, the burden of 18F-DOPA-avid metastatic disease was far greater compared to the burden of 68Ga-HA-DOTATATE-avid metastatic disease.

Published in European Journal of Hybrid Imaging

ISSN: 2510-3636 (Online)
Publisher: SpringerOpen
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
Website: https://ejhi.springeropen.com

About the journal

Abstract

Keywords